FSN Ref: 200-23-030-001 FSCA Ref: 200-23-030-002

Date: 13.11.2023

Urgent Field Safety Notice Comfort marker 2.0 Safety Needle

For Attention of*:End users of the Comfort Marker 2.0 Safety Needle with batch numbers 20220525001

Contact details of local representative (name, e-mail, telephone, address etc.)*

Roland Kortenhorst, kortenhorst@medicalprecision.nl, +31(6)51606402, Medical Precision B.V., Telfordstraat 9-30, 8013RL, Zwolle, Netherlands

FSN Ref: 200-23-030-001 FSCA Ref: 200-23-030-002

Urgent Field Safety Notice (FSN) Device Commercial Name Risk addressed by FSN

1. Information on Affected Devices*

1 Device Type(s)*

Comfort Marker 2.0 Safety Needle, that is used together with Comfort Marker 2.0 to place reference marks on the patients undergoing radiotherapy treatments. Safety Needles as provided in the marking set, in a white box that includes 25 Safety Needles.



- 1 2. Commercial name(s)
- Comfort Marker 2.0 Safety Needle
- 1 3. Unique Device Identifier(s) (UDI-DI)
- 8720165025MP CM2022LV
- 1 4. Primary clinical purpose of device(s)*
- Needles to be used with Comfort Marker 2.0 system for placement of markings on human skin for radiotherapy treatments.
- 1 5. Device Model/Catalogue/part number(s)
- . 2022
- 1 6. Software version
 - N.A.
- 1 7. Affected serial or lot number range
- . 20220525001
- 1 8. Associated devices
- . N.A.

2 Reason for Field Safety Corrective Action (FSCA)*

2 1. Description of the product problem*

Comfort Marker 2.0 Safety Needle, that is used together with device Comfort Marker 2.0 for placement of markings on human skin for radiotherapy treatments was CE certified by ECM for a shelf life of 1 year. All the tests, including real time aging that were performed to support 1 year shelf life initially claimed and were successful. Furthermore, same shelf life confirmatory tests were also performed on a 2-year real-time aged Safety Needle with the goal to collect evidence for extension of the originally claimed shelf life of the Safety Needle to two years. All the performed tests were successfully passed by two year real aged samples.

2

2

2

N/A

FSN Ref: 200-23-030-001 FSCA Ref: 200-23-030-002

Consequently, it was deemed sufficient proof by the regulatory expert involved during that period with the Medical Precision B.V. to support the safe performance of the Safety Needle after increased storage time and extension of the shelf life of 2 years was implemented. However, Medical Precision did not officially submit this change to the overseeing Notified Body ECM for review and approval. During the surveillance audit by the ECM the unsupervised shelf life extension became known to the auditor and actions deemed passing for the nonconformity were taken. It should be stated that there is no risks for end users or patients in using Safety Needle with two year shelf life, since all the proof of it safe performance after two years was collected and was reviewed by the auditor. Nevertheless, as the prescribed change process was not followed, the extension of the shelf life was not accepted by the auditor and remediating actions to return the claimed for the Safety Needle to the approved by the ECM during CE certification one year was mandated. Present FSCA is initiated to communicate corrected one year shelf life to the customers in possession of the Safety Needle with the claimed two year shelf life. Hazard giving rise to the FSCA Regulatory noncompliance with the overseeing Notified Body ECM. Shelf life extension for the Safety Needle was not duly submitted and reviewed by the overseeing Notified Body ECM. However, there is no risks for end users or patients in using Safety Needle with two year shelf life, since all the proof of its safe performance after two years was collected and was reviewed by the ECM auditor. Probability of problem arising Using of the Safety Needle past its officially cleared by ECM one year shelf life. The label states two year shelf life which is not approved by ECM Predicted risk to patient/users No risk for end users and patients. It is regulatory noncompliance. 5. Further information to help characterise the problem N/A Background on Issue Regulatory expert involved with the Medical Precision deemed sufficient obtained via tests evidence of safe performance of the Safety Needle after two years storage. Shelf life increase to two years was implemented without notification of the overseeing Notified Body ECM.

	3. Type of Action to mitigate the risk*			
3.	1.	1. Action To Be Taken by the User*		
		 ☑ Identify Device ☐ Quarantine Device ☐ Return Device ☐ Destroy Device 		
		☐ On-site device modification/inspection		
		☐ Follow patient management recommendations		
		$\hfill\Box$ Take note of amendment/reinforcement of Instructions For Use (IFU)		
		 User shall identify the batch number of the Safety Needles that they have in stock User shall fill in the form attached to the document 200-23-030-003_20231114 Statement for end users & form 		
		 User shall decide on the following action: use the Safety Needle as is with taking into account 1 year shelf life or ship the Safety Needle back to be exchanged 		

Other information relevant to FSCA

Rev 1: September 2018 FSN Ref: 200-23-030-001

FSN Ref: 200-23-030-001 FSCA Ref: 200-23-030-002

3.	2.	By when should the action be completed?	Form that is part of the document 200-23-030-003_20231114 Statement for end users & form shall be filled in and share with Medical Precision by 30-Nov-2023.		
3.	3.	Particular considerations for	Choose an item.		
	Is follow-up of patients or review of patients' previous results recommended?				
		Provide further details of patient-level follow-up if required or a justification why none is required			
3.	4.	Is customer Reply Require	d? * No		
	(If	(If yes, form attached specifying deadline for return)			
3.	5.	Action Being Taken by	the Manufacturer		
	 Software upgrade				
3	6.	By when should the	Date added to the above identified actions in order to specify		
		action be completed?	completion date per action.		
3.	7.	Is the FSN required to be of /lay user?	communicated to the patient N/A		
3	8.	8. If yes, has manufacturer provided additional information suitable for the patient/lay			
	user in a patient/lay or non-professional user information letter/sheet?				
1	Choose an item. Choose an item.				

FSN Ref: 200-23-030-001 FSCA Ref: 200-23-030-002

	4.	General Information*		
4.	1. FSN Type*	New		
4.	For updated FSN, reference number and date of previous FSN	Provide reference and date of previous FSN if relevant		
4.	3. For Updated FSN, key new inform	nation as follows:		
	Summarise any key difference in dev	rices affected and/or action to be taken.		
4.	4. Further advice or information already expected in follow-up FSN? *			
4	If follow-up FSN expected, what is Eg patient management, device mod	s the further advice expected to relate to: ifications etc		
4	Anticipated timescale for follow- up FSN	For provision of updated advice.		
4.	7. Manufacturer information (For contact details of local representative refer to page 1 of this FSN)			
	a. Company Name	Only necessary if not evident on letter-head.		
	b. Address	Only necessary if not evident on letter-head.		
	c. Website address	Only necessary if not evident on letter-head.		
4.	8. The Competent (Regulatory) Authority of your country has been informed about this communication to customers. *Yes, Medical Precision is located in Netherlands and Health and Youth Care Inspectorate is informed.			
4.	9. List of attachments/appendices:	If extensive consider providing web-link instead.		
4.	10. Name/Signature	Roland Kortenhorst, CEO		

Transmission of this Field Safety Notice This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate) Please transfer this notice to other organisations on which this action has an impact. (As appropriate) Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action. Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback..*

Note: Fields indicated by * are considered necessary for all FSNs. Others are optional.